COVID-19: Regulatory response and compliance impacts has been saved

Close
LIFE SCIENCES

Office of Inspector General releases special fraud alert for speaker programs
Highlights from the special fraud alert
false

Close
LIFE SCIENCES

AdvaMed releases new compliance guidance related to the COVID-19 response
Explore highlights from the new compliance guidance and recommendations for companies to move forward.
false

Close
LIFE SCIENCES

COVID-19’s impact on government programs, commercial contracting, and gross-to-net
Through our analysis of the regulatory environment, we discuss how these changes have begun to affect prescription drug coverage, channel distribution, government programs, and commercial contract spending and reimbursement.
false

Close
LIFE SCIENCES

Life sciences compliance considerations and challenges amidst COVID-19
As we are seeing firsthand, managing a complex crisis like COVID-19 can be extremely challenging. Routine approaches and single-issue responses or action plans may not be effective in unprecedented times.
false